BrightGene Bio Medical Technology C Strategic Asset Allocation Index
BrightGene Bio Medical Technology C strategic asset allocation index. BrightGene Bio Medical Technology C (688166) has a Strategic Asset Allocation Index of 97.1% as of June 2023. Strategic assets (PP&E of CN¥2.29 Billion plus long-term investments of CN¥-) total CN¥2.29 Billion, measured against net assets of CN¥2.35 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check BrightGene Bio Medical Technology C (688166) tangible equity ratio to evaluate the tangible quality of the company's equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of BrightGene Bio Medical Technology C (2016–2022)
Strategic asset allocation index of BrightGene Bio Medical Technology C from 2016 to 2022. This chart shows how BrightGene Bio Medical Technology C's Strategic Asset Allocation Index has evolved across 7 annual periods from 2016 to 2022. As of June 2023, the index stands at 97.1%, representing strategic assets of CN¥2.29 Billion against net assets of CN¥2.35 Billion CNY.
BrightGene Bio Medical Technology C Strategic Asset Allocation Index by Year (2016–2022)
BrightGene Bio Medical Technology C strategic asset allocation index by year from 2016 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for BrightGene Bio Medical Technology C from 2016 to 2022, covering 7 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market cap of BrightGene Bio Medical Technology C.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 92.6% | CN¥2.08 Billion | CN¥2.08 Billion | CN¥- | CN¥2.24 Billion | ▲ +13.5 pp |
| 2021 | 79.1% | CN¥1.38 Billion | CN¥1.38 Billion | CN¥- | CN¥1.74 Billion | ▲ +47.6 pp |
| 2020 | 31.6% | CN¥452.50 Million | CN¥452.50 Million | CN¥- | CN¥1.43 Billion | ▲ +13.0 pp |
| 2019 | 18.6% | CN¥244.69 Million | CN¥244.69 Million | CN¥- | CN¥1.31 Billion | ▼ -10.0 pp |
| 2018 | 28.7% | CN¥221.59 Million | CN¥221.59 Million | CN¥- | CN¥772.85 Million | ▼ -5.2 pp |
| 2017 | 33.9% | CN¥151.20 Million | CN¥151.20 Million | CN¥- | CN¥446.02 Million | ▼ -26.8 pp |
| 2016 | 60.7% | CN¥133.59 Million | CN¥133.59 Million | CN¥- | CN¥220.15 Million | — |